

Comprehensive management of antidepressant therapy in pediatric psychiatry

Juciane Valentim



10.56238/rcsv14n4-017

ABSTRACT


The management of antidepressant medications in children and adolescents involves careful consideration due to their unique pharmacokinetic and pharmacodynamic profiles. Pharmacists are integral to this process, ensuring medications are used correctly and monitoring for efficacy and adverse effects. Antidepressants are prescribed for various conditions including major depression, obsessive-compulsive disorder, and anxiety disorders. Given the age-specific metabolic differences, treatment must be tailored and closely monitored for side effects such as weight gain, sleep disturbances, and impacts on neuromotor development. The review by Cardy, Dhaliwal, and Reddy (2017) highlights the increased use of antidepressants in pediatric patients since the late 1990s, with a resurgence after a brief decline due to regulatory concerns. The prevalence of off-label prescribing, despite limited FDA approval for many antidepressants in this age group, raises important questions about their efficacy and safety. Walkup (2017) emphasizes the pharmacist's role in managing these treatments, stressing the need for careful monitoring and individualized treatment plans. Taurines et al. (2011) outline the importance of combining antidepressant therapy with non-pharmacological interventions such as psychotherapy for managing severe depressive symptoms. Hetrick et al. (2012) review the effectiveness of newer antidepressants, particularly SSRIs, noting modest benefits but also an increased risk of suicide-related outcomes, recommending fluoxetine as a first-choice option. Díaz-Caneja et al. (2014) investigate the rise of polypharmacy involving antidepressants and other psychotropic drugs, highlighting the need for more research to understand its efficacy and safety. Lastly, Luft et al. (2018) address the issue of activation symptoms associated with antidepressants, underscoring the need for better understanding and management. Overall, a collaborative approach involving pharmacists, clinicians, and researchers is essential to ensure safe and effective antidepressant therapy for pediatric patients, emphasizing the need for continued research and evidence-based practices.

Keywords: Pediatric Psychiatry, Antidepressants, Pharmacists, Polypharmacy, Activation Symptoms.

INTRODUCTION

The management of depressive disorders in children and adolescents often involves the use of antidepressant medications, which must be administered with care due to the unique characteristics of this age group. Pharmacists play a crucial role in ensuring the correct use of these medications, optimizing treatment while minimizing risks and maximizing benefits. Antidepressants are prescribed for conditions such as major depression, obsessive-compulsive disorder, and anxiety disorders. Due to differences in pharmacokinetics and pharmacodynamics in younger populations compared to adults, medications must be tailored to individual needs, with close monitoring of side effects such as weight gain, sleep disturbances, and impacts on neuromotor development.

Figure 1: Percent prevalence of antidepressant use in children and adolescents (0–19 years) in youth cohorts from five countries, 2005–2012. Annotation: DE=Germany, DK=Denmark, NL=Netherlands, UK= United Kingdom, USA=United States of America. Source: Bachmann et al. (2016).



Cardy, Dhaliwal, and Reddy (2017) discuss the increased use of antidepressants in children and adolescents since the late 1990s, noting a resurgence after a temporary decline due to regulatory warnings. Despite many antidepressants not being officially approved for pediatric use, off-label prescribing remains common. This review highlights concerns about efficacy, tolerability, and safety, emphasizing the need for personalized treatment approaches and further research, particularly regarding naturalistic studies.

Walkup (2017) emphasizes the pharmacist's critical role in managing antidepressant treatments for young patients, underscoring the need for careful monitoring due to age-specific pharmacokinetic and pharmacodynamic differences. Pharmacists must navigate dosage adjustments, potential drug interactions, and side effects while providing ongoing support and education to patients and their families. This detailed approach is crucial for optimizing therapeutic outcomes and ensuring safety.

Taurines et al. (2011) provide a comprehensive overview of antidepressant use in children and adolescents, highlighting the importance of non-pharmacological interventions like psychotherapy for mild to moderate symptoms and the role of medications like fluoxetine for severe cases. They discuss the need for informed consent when using off-label medications and outline therapeutic strategies for managing depressive disorders.

Hetrick et al. (2012) investigate the efficacy and safety of newer generation antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), in treating pediatric depressive disorders. The review of nineteen trials reveals modest benefits in reducing depression severity and improving remission rates but also highlights an increased risk of suicide-related outcomes. The study calls for


caution in interpreting results due to methodological limitations and suggests fluoxetine as a first-choice medication if needed.

Díaz-Caneja et al. (2014) review the epidemiology of polypharmacy involving antidepressants and other psychotropic drugs in children and adolescents. Their findings indicate a rise in such practices, particularly combining antidepressants with stimulants and antipsychotics. The study points to preliminary evidence supporting some polypharmacy patterns but calls for more research to better understand their efficacy and safety.

Luft et al. (2018) address the issue of antidepressant tolerability in youth, focusing on activation symptoms such as impulsivity and insomnia. Despite being identified as a side effect in the 1990s, activation remains poorly understood. The study examines its pathophysiology, predictors, and offers guidance on managing these symptoms in young patients.

Finally, Lawrence et al. (2017) provide a detailed review of antidepressant use in treating pediatric depression, addressing key questions about efficacy, comparison to psychotherapy, long-term outcomes, FDA approval, and risk of suicidality. The review offers valuable insights for clinicians on navigating the complexities of antidepressant treatment in young patients and provides practical recommendations for its application in clinical practice.

Figure 2: Trends in antidepressant medication use in children and adolescents (0–19 years) in youth cohorts from five countries for tricyclic antidepressants and selective serotonin reuptake inhibitors (2005 vs. 2012). Annotation: DE=Germany, DK=Denmark, NL=The Netherlands, SSRI=Selective Serotonin Reuptake Inhibitors, TCA=Tricyclic antidepressants, UK=United Kingdom, USA=United States of America. Source: Bachmann et al. (2016).



Pharmaceutical care is therefore crucial to ensuring that the use of antidepressants in children and adolescents is safe and effective. The expertise of pharmacists in medication management, monitoring adverse effects, and providing ongoing education significantly contributes to improving therapeutic outcomes and promoting the mental health of young patients.

In conclusion, the management of antidepressant therapy in children and adolescents requires a nuanced and vigilant approach, given the distinct pharmacokinetic and pharmacodynamic characteristics of this population. The studies reviewed underscore the growing use of antidepressants despite the challenges and controversies surrounding their efficacy, safety, and approval status. Pharmacists play a pivotal role in this context, ensuring that medications are administered safely and effectively while minimizing risks and addressing potential side effects. Their involvement is crucial in providing personalized care, educating patients and their families, and monitoring ongoing treatment.

The literature reveals that while antidepressants can offer modest benefits in treating depressive and anxiety disorders in young people, their use must be carefully balanced with potential risks, including increased risk of suicidal thoughts and behaviors. The evolving nature of antidepressant prescriptions, including the use of polypharmacy and off-label treatments, highlights the need for continued research and evidence-based practice.

Ultimately, a collaborative approach involving pharmacists, clinicians, and researchers is essential for optimizing antidepressant therapy in pediatric populations. By staying informed about the latest evidence, embracing a careful and individualized treatment strategy, and advocating for further research, healthcare professionals can significantly contribute to the safety and effectiveness of mental health treatments for children and adolescents, fostering better outcomes and improved quality of life for young patients.

REFERENCES

1. Bachmann, C. J., Aagaard, L., Burcu, M., Glaeske, G., Kalverdijk, L. J., Petersen, I., ... & Hoffmann, F. (2016). Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005–2012. **European Neuropsychopharmacology*, 26*(3), 411-419.
2. Cardy, R., Dhaliwal, S., & Reddy, P. (2017). Antidepressant drug treatment in Child and adolescent Psychiatry. **MJEM*, 1*, 31-39. <https://doi.org/10.18689/MJEM-1000106>.
3. Díaz-Caneja, C., Espliego, A., Parellada, M., Arango, C., & Moreno, C. (2014). Polypharmacy with antidepressants in children and adolescents. **The International Journal of Neuropsychopharmacology*, 17*(7), 1063-1082. <https://doi.org/10.1017/S1461145712001265>.
4. Hetrick, S., McKenzie, J., Cox, G., Simmons, M., & Merry, S. (2012). Newer generation antidepressants for depressive disorders in children and adolescents. **The Cochrane Database of Systematic Reviews*, 11*, CD004851. <https://doi.org/10.1002/14651858.CD004851.pub3>.
5. Lawrence, H., Nangle, D., Schwartz-Mette, R., & Erdley, C. (2017). Medication for Child and Adolescent Depression: Questions, Answers, Clarifications, and Caveats. **Practice Innovations*, 2*, 39-53. <https://doi.org/10.1037/pri0000042>.
6. Luft, M., Lamy, M., DelBello, M., McNamara, R., & Strawn, J. (2018). Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition, and Management. **Current Problems in Pediatric and Adolescent Health Care*, 48*(2), 50-62. <https://doi.org/10.1016/j.cppeds.2017.12.001>.
7. Taurines, R., Gerlach, M., Warnke, A., Thome, J., & Wewetzer, C. (2011). Pharmacotherapy in depressed children and adolescents. **The World Journal of Biological Psychiatry*, 12*, 11-15. <https://doi.org/10.3109/15622975.2011.600295>.
8. Walkup, J. (2017). Antidepressant Efficacy for Depression in Children and Adolescents: Industry- and NIMH-Funded Studies. **The American Journal of Psychiatry*, 174*(5), 430-437. <https://doi.org/10.1176/appi.ajp.2017.16091059>.